Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

This study (ATRiBRAVE) is testing a combination approach in people with advanced triple-negative breast cancer (TNBC) — a type that lacks hormone receptors and HER2 — that stopped responding to immunotherapy earlier. The treatment uses a drug called ceralasertib to sensitize the cancer, followed by immunotherapy (durvalumab) plus chemotherapy (nab-paclitaxel). **You may be eligible if...** - You are 18 or older - You have advanced triple-negative breast cancer - Your cancer was previously treated with immunotherapy and chemotherapy for early-stage disease, but has since progressed - You have not received chemotherapy for your advanced (metastatic) disease yet - A tumor tissue sample is available - You can swallow tablets **You may NOT be eligible if...** - You have already received chemotherapy for advanced/metastatic disease - You are unable to swallow oral medication - You have significant other health conditions that make the treatment unsafe Talk to your doctor to see if this trial is right for you.